

ABSTRACT

5 The present invention provides heregulin variants
that are capable of binding an ErbB receptor. Included
in the invention are variants of human heregulins, and,
in particular, variants of human heregulin- β 1 having
enhanced affinity for the ErbB-3 and ErbB-4 receptors.

10. These variants include at least one amino acid
substitution and can include further modifications.
The invention also provides nucleic acid molecules
encoding heregulin variants and related vectors, host
cells, pharmaceutical compositions, and methods.